Reemergence of positive symptoms after initial response to risperidone

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 383-386

  Cung, Donna D ^a   Stimmel, Glen L ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; HALLUCINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; RECURRENCE RISK; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; HUMANS; MALE; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA;

EID: 0030899821     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Cohen LJ. Risperidone. Pharmacotherapy 1994;14:253-65.
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
3. Curtis VA, Kerwin RW. A risk-benefit assessment of risperidone in schizophrenia. Drug Safety 1995;12:139-45.
4. Stimmel GL. Schizophrenia. In: Herfindal ET, Gourley DR, eds. Textbook of therapeutics: drug and disease management. Baltimore: Williams & Wilkins, 1996:1117-31.
5. Stip E, Tourjman V, Lew V, et al. "Awakenings" effect with risperidone [letter]. Am J Psychiatry 1995;152:1833